| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4005332 | American Journal of Ophthalmology | 2008 | 12 Pages |
Abstract
Despite the small number of patients studied, the marked improvement in VA accompanied by prominent reductions in foveal thickness, fluorescein leakage, and area of CNV suggest a beneficial effect. It may be worthwhile to consider further evaluation of systemic bevacizumab in young patients with CNV.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Quan Dong Nguyen, Syed Mahmood Shah, Gulnar Hafiz, Diana V. Do, Julia A. Haller, Roberto Pili, Ingrid E. Zimmer-Galler, Kashif Janjua, R.C. Andrew Symons, Peter A. Campochiaro,